Related Experiment Videos
Overview and meta-analysis of randomised trials of amiodarone in chronic heart failure
M Piepoli1, G Q Villani, P Ponikowski
1Cardiac Medicine Department, Royal Brompton Hospital, London, UK.
Insights
Amiodarone benefits patients with left ventricular dysfunction, reducing deaths by 20-25% in heart failure patients. However, this antiarrhythmic drug significantly increases side effects by over 120%.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Amiodarone, an antiarrhythmic drug, shows potential benefits in patients with left ventricular dysfunction, unlike other Class I agents.
- Preliminary studies indicated positive outcomes, prompting further large-scale investigations.
Purpose of the Study:
- To review the results of randomized controlled studies on amiodarone in patients with left ventricular dysfunction.
- To discuss controversial aspects regarding amiodarone's efficacy and safety profile.
Main Methods:
- Meta-analysis of randomized controlled trials.
- Review of existing literature on amiodarone's effects in heart failure and left ventricular dysfunction.
Main Results:
- Amiodarone use in heart failure was associated with a 20-25% reduction in mortality.
- A significant increase in side effects, ranging from 120-124%, was observed with amiodarone treatment.
Conclusions:
- Amiodarone demonstrates a mortality benefit in heart failure patients with left ventricular dysfunction.
- The substantial increase in adverse events necessitates careful consideration of the risk-benefit ratio.
Abstract:
Unlike other antiarrhythmic class I drugs, amiodarone showed in preliminary studies, benefits also in patients with left ventricular dysfunction. These positive results have induced the development of large randomised controlled studies: their results are reviewed and the controversial points are discussed. In a meta-analysis of randomised controlled trials the use of amiodarone in heart failure was associated with an approximate 20 to 25% reduction in deaths. However, amiodarone was also associated with a 120 to 124% increase in side effects.